These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37330302)

  • 1. Identification of prognostic melatonin-related lncRNA signature in tumor immune microenvironment and drug resistance for breast cancer.
    Gao SC; Wu MD; Zhang XX; Liu YF; Wang CL
    Asian J Surg; 2023 Sep; 46(9):3529-3541. PubMed ID: 37330302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mitochondrial function-related LncRNA signature predicts prognosis and immune microenvironment for breast cancer.
    Wang Y; Gao S; Xu Y; Tang Z; Liu S
    Sci Rep; 2023 Mar; 13(1):3918. PubMed ID: 36890266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the expression and prognostic significance of m
    Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
    Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
    Yu Z; Zhu Y; Ji J
    Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
    Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
    Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Pyroptosis-Associated Long Non-coding RNA Signature Predicts Prognosis and Tumor Immune Microenvironment of Patients With Breast Cancer.
    Ping L; Zhang K; Ou X; Qiu X; Xiao X
    Front Cell Dev Biol; 2021; 9():727183. PubMed ID: 34616734
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
    Xiao R; Yang M; Tan Y; Ding R; Li D
    Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.
    Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F
    J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.
    Zhang X; Zhang X; Li G; Hao Y; Liu L; Zhang L; Chen Y; Wu J; Wang X; Yang S; Xu S
    J Immunol Res; 2022; 2022():3143511. PubMed ID: 35578667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.
    Li C; Zhang Y
    BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
    Yang M; Sun Y; Ji H; Zhang Q
    Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
    Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer.
    Luo Y; Zhang Y; Wu YX; Li HB; Shen D; Che YQ
    J Clin Lab Anal; 2022 Jan; 36(1):e24172. PubMed ID: 34894405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A four-gene signature in the tumor microenvironment that significantly associates with the prognosis of patients with breast cancer.
    Wang J; Yang Z; Zhang C; Ouyang J; Zhang G; Wu C
    Gene; 2020 Nov; 761():145049. PubMed ID: 32791092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A six-gene-based signature for breast cancer radiotherapy sensitivity estimation.
    Chen X; Zheng J; Zhuo ML; Zhang A; You Z
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33179733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
    Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.